ABSTRACT
INTRODUCTION: Obeticholic acid (OCA) and fibrates therapy results in biochemical improvement in placebo-controlled trials in patients with primary biliary cholangitis and insufficient response to ursodeoxycholic acid. There is scarce information outside of clinical trials. Therefore, we have assessed the effectiveness and adverse events of these treatments. METHODS: Data from patients included in the ColHai registry treated with OCA, fibrates, or both were recorded during a year, as well as adverse events and treatment discontinuation. RESULTS: Eighty-six patients were treated with OCA, 250 with fibrates (81% bezafibrate; 19% fenofibrate), and 15 with OCA plus fibrates. OCA group had baseline significantly higher alkaline phosphatase (ALP) (P = 0.01) and lower platelets (P = 0.03) than fibrates. Both treatments significantly decreased ALP, gamma-glutamyl transferase (GGT), and transaminases and improved Globe score. Albumin and immunoglobulin type M improved in the fibrates group. ALP decrease was higher under fibrates, whereas alanine aminotransferase decline was higher under OCA. Although baseline transaminases and GGT were higher in patients with OCA plus fibrates, significant ALP, GGT, alanine aminotransferase, and Globe score improvement were observed during triple therapy. Adverse events were reported in 14.7% of patients (21.3% OCA; 17.6% fenofibrate; 10.7% bezafibrate), mainly pruritus (10.1% with OCA). Discontinuation was more frequent in fenofibrate treatment mainly because of intolerance or adverse events. DISCUSSION: Second-line therapy with OCA or fibrates improves hepatic biochemistry and the GLOBE score in primary biliary cholangitis patients with suboptimal response to ursodeoxycholic acid. Simultaneous treatment with OCA and fibrates improved ALP as well.
Subject(s)
Bezafibrate/therapeutic use , Chenodeoxycholic Acid/analogs & derivatives , Fenofibrate/therapeutic use , Liver Cirrhosis, Biliary/drug therapy , Chenodeoxycholic Acid/therapeutic use , Female , Humans , Male , Middle Aged , Retrospective Studies , Treatment OutcomeSubject(s)
Colonic Neoplasms/pathology , Lipoma/pathology , Humans , Male , Middle Aged , Remission, SpontaneousABSTRACT
Resumen Los tumores neuroendocrinos del tubo digestivo son lesiones muy poco frecuentes. Se presenta el caso de una mujer de 57 años de edad que consulta por síndrome tóxico, vómitos y diarrea de 3 meses de evolución, con diagnóstico final de tumor neuroendocrino pobremente diferenciado. A partir de esta observación clínica se revisan las características clínicas y procedimientos diagnósticos, los factores pronósticos y las posibilidades terapéuticas en este tipo de tumores. Ante una tumoración colónica con metástasis hepáticas hiperecogénicas se debe considerar siempre el diagnóstico de tumor neuroendocrino (AU)
Abstract Neuroendocrine tumors of the gastrointestinal tract are highly infrequent. We report the case of a 57-year-old woman who presented with toxic syndrome, vomiting and a 3-month history diarrhea, with a final diagnosis of poorly-differentiated neuroendocrine tumor. Based on this case, we review the clinical characteristics, diagnostic procedures, prognostic factors and therapeutic possibilities in this type of tumor. Neuroendocrine tumors should be considered in the diagnosis of colonic tumors with hyperechoic liver metastases (AU)
Subject(s)
Humans , Female , Middle Aged , Carcinoma, Neuroendocrine/pathology , Colonic Neoplasms/pathology , Neoplasm Metastasis/pathology , Endoscopy, Digestive SystemABSTRACT
Neuroendocrine tumors of the gastrointestinal tract are highly infrequent. We report the case of a 57-year-old woman who presented with toxic syndrome, vomiting and a 3-month history diarrhea, with a final diagnosis of poorly-differentiated neuroendocrine tumor. Based on this case, we review the clinical characteristics, diagnostic procedures, prognostic factors and therapeutic possibilities in this type of tumor. Neuroendocrine tumors should be considered in the diagnosis of colonic tumors with hyperechoic liver metastases.
Subject(s)
Carcinoma, Neuroendocrine/pathology , Carcinoma, Neuroendocrine/secondary , Colonic Neoplasms/pathology , Liver Neoplasms/secondary , Female , Humans , Middle AgedSubject(s)
Humans , Female , Middle Aged , Irritable Bowel Syndrome/complications , Abdominal Pain/etiology , LaparoscopyABSTRACT
Presentamos el caso clínico de un varón de 40 años con hepatopatía alcohólica de base que presenta fiebre prolongada, ictericia e insuficiencia hepática asociados a infección por Coxiella burnetti. Tras el diagnóstico y el tratamiento antibiótico adecuado el paciente se recuperó por completo. Se documenta el caso adecuadamente y, a propósito del mismo, se revisa de forma práctica la literatura y se discute la importancia de esta infección, y la necesidad de insistir en su inclusión en el diagnóstico diferencial ante a esta situación clínica (AU)
We report the case of a 40-year-old man with underlying alcoholic liver disease who presented with prolonged fever, jaundice and liver failure associated with Coxiella burnetii infection. After diagnosis and appropriate antibiotic treatment, the patient made a complete recovery. We describe aspects of this case and provide a practical review of the literature on the topic. We also discuss the importance of this infection and the need for its inclusion in the differential diagnosis of this clinical picture (AU)
Subject(s)
Humans , Animals , Male , Adult , Fatty Liver, Alcoholic/complications , Fever of Unknown Origin/etiology , Jaundice/etiology , Q Fever/complications , Environmental Exposure , Immunocompromised Host , Liver Cirrhosis, Alcoholic/complications , Q Fever/diagnosisABSTRACT
We report the case of a 40-year-old man with underlying alcoholic liver disease who presented with prolonged fever, jaundice and liver failure associated with Coxiella burnetii infection. After diagnosis and appropriate antibiotic treatment, the patient made a complete recovery. We describe aspects of this case and provide a practical review of the literature on the topic. We also discuss the importance of this infection and the need for its inclusion in the differential diagnosis of this clinical picture.
Subject(s)
Fatty Liver, Alcoholic/complications , Fever of Unknown Origin/etiology , Jaundice/etiology , Q Fever/complications , Acetaminophen/adverse effects , Adult , Animals , Animals, Domestic , Antibodies, Bacterial/blood , Antipyretics/adverse effects , Ascites/etiology , Chemical and Drug Induced Liver Injury/complications , Coxiella burnetii/immunology , Diagnosis, Differential , Disease Reservoirs , Environmental Exposure , Humans , Immunocompromised Host , Liver Cirrhosis, Alcoholic/complications , Liver Failure/etiology , Male , Malnutrition/complications , Q Fever/diagnosis , ZoonosesABSTRACT
Antiviral treatment can be complex in decompensated hepatitis B virus (HBV) cirrhosis because of potential emergence of lamivudine-resistant mutants and worsening liver function, and to multifactorial nephrotoxicity. Negative HBV-DNA status by hybridization before liver transplantation is a favorable prognostic factor. We present the case of a 54-year-old HBV+ liver transplantation candidate who, after testing negative for HBV-DNA, developed YMDD lamivudine-resistant mutants resulting in a deteriorated clinical condition. After 8 months of adefovir plus lamivudine double therapy, only partial response was achieved. Tenofovir was added to this regimen, and an early decline of HBV-DNA was seen at 4 weeks without adverse events. The patient underwent transplantation. At 21-month postoperative follow-up, the patient's outcome was excellent. Post-transplantation HBV prophylaxis, taking into account the prior development of mutants, consists of hepatitis B immunoglobulin plus lamivudine and adefovir. Tenofovir was well tolerated and produced a fast antiviral response, suggesting its potential value in combined antiviral treatment for liver transplantation candidates.
